Analysts predict Abbott’s Q4 earnings will rise, reflecting strong growth in key metrics
Chicago: Analysts are buzzing about Abbott’s upcoming earnings report. They expect the company to announce earnings of $1.34 per share, which is a nice jump of 12.6% from last year. Revenue is also looking good, projected to hit $11.02 billion, up 7.6% from the same quarter last year.
Interestingly, the earnings per share estimate hasn’t changed in the last month. This shows that analysts have been pretty consistent in their outlook for Abbott.
Before earnings are released, it’s crucial to look at any changes in estimates. This can give us a clue about how investors might react. Research shows that when earnings estimates change, it often affects stock prices in the short term.
Investors usually check consensus earnings and revenue estimates to see how the company performed. But digging into specific metrics can provide even more insight.
So, let’s break down what analysts are predicting for Abbott’s key metrics. For instance, they expect net sales from Medical Devices in Rhythm Management to be around $623.50 million, which is a 7.1% increase from last year.
For Diabetes Care, analysts are forecasting net sales of $1.82 billion, marking a 17.3% rise. Meanwhile, Established Pharmaceuticals are expected to bring in $1.31 billion, up 6.9% from the previous year.
When it comes to Diagnostics, the estimate is $2.57 billion, showing a slight increase of 1.4%. In the U.S. alone, Diagnostics sales are projected at $1.03 billion, a modest 0.9% increase.
Internationally, Diagnostics sales are expected to reach $1.54 billion, up 1.7%. For Nutrition, analysts predict $1.21 billion in international sales, a 3.1% increase, while U.S. Nutrition sales are estimated at $942.92 million, up 9.6%.
Looking at Medical Devices, Neuromodulation sales are expected to hit $50.56 million, a 17.6% increase. Rhythm Management in the U.S. is projected at $303.63 million, up 6.5%.
Internationally, Rhythm Management sales are expected to be around $318.99 million, a 7.4% increase. Lastly, Structural Heart sales in the U.S. are forecasted to reach $279.89 million, showing a significant 21.2% rise.
Overall, Abbott’s stock has dipped slightly by 0.7% over the past month, while the S&P 500 composite has dropped 3.3%. With a Zacks Rank of #2 (Buy), analysts believe ABT will outperform the market soon.
